{"pmid":32422144,"title":"Perforin and resistance to SARS coronavirus 2.","text":["Perforin and resistance to SARS coronavirus 2.","J Allergy Clin Immunol","Cunningham, Louise","Simmonds, Peter","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul","32422144"],"journal":"J Allergy Clin Immunol","authors":["Cunningham, Louise","Simmonds, Peter","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422144","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jaci.2020.05.007","keywords":["bcg","covid","hlh","mas","sars","sars-cov-2","coronavirus","cytokine release","cytokine storm","cytotoxic t lymphocyte","metformin","natural killer","perforin","perforinopathy"],"topics":["Mechanism"],"weight":1,"_version_":1667159284546273280,"score":9.490897,"similar":[{"pmid":32380318,"pmcid":"PMC7198409","title":"Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.","text":["Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.","Autoimmun Rev","Cunningham, Louise","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul","32380318"],"journal":"Autoimmun Rev","authors":["Cunningham, Louise","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380318","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102563","keywords":["covid-19","cytokine storm","il-6","interleukin-6","macrophage activation syndrome","natural killer cells","perforin","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666597097381560320,"score":60.90449},{"pmid":32283324,"pmcid":"PMC7151358","title":"COVID-19 - Considerations for the paediatric rheumatologist.","text":["COVID-19 - Considerations for the paediatric rheumatologist.","The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lifes across the globe. A significant proportion of adult patients require hospitalisation and may develop severe life-threatening complications. Children, on the other hand, can carry and transmit the virus, but usually do not develop severe disease. Mortality in the paediatric age-group is relatively low. Differences in virus containment and clearance, as well as reduced inflammation-related tissue and organ damage may be caused by age-specific environmental and host factors. Since severe complications in adults are frequently caused by uncontrolled immune responses and a resulting \"cytokine storm\" that may be controlled by targeted blockade of cytokines, previously established treatment with immunosuppressive treatments may indeed protect children from complications.","Clin Immunol","Hedrich, Christian M","32283324"],"abstract":["The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lifes across the globe. A significant proportion of adult patients require hospitalisation and may develop severe life-threatening complications. Children, on the other hand, can carry and transmit the virus, but usually do not develop severe disease. Mortality in the paediatric age-group is relatively low. Differences in virus containment and clearance, as well as reduced inflammation-related tissue and organ damage may be caused by age-specific environmental and host factors. Since severe complications in adults are frequently caused by uncontrolled immune responses and a resulting \"cytokine storm\" that may be controlled by targeted blockade of cytokines, previously established treatment with immunosuppressive treatments may indeed protect children from complications."],"journal":"Clin Immunol","authors":["Hedrich, Christian M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283324","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.clim.2020.108420","keywords":["ards","covid","cytokine storm","inflammation","paediatric","rheumatology","sars","sars-cov2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491520548864,"score":58.318077},{"pmid":32387301,"title":"The CoV-2 outbreak: how hematologists could help to fight Covid-19.","text":["The CoV-2 outbreak: how hematologists could help to fight Covid-19.","COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.","Pharmacol Res","Galimberti, Sara","Baldini, Chiara","Barate, Claudia","Ricci, Federica","Balducci, Serena","Grassi, Susanna","Ferro, Francesco","Buda, Gabriele","Benedetti, Edoardo","Fazzi, Rita","Baglietto, Laura","Lucenteforte, Ersilia","Di Paolo, Antonello","Petrini, Mario","32387301"],"abstract":["COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed."],"journal":"Pharmacol Res","authors":["Galimberti, Sara","Baldini, Chiara","Barate, Claudia","Ricci, Federica","Balducci, Serena","Grassi, Susanna","Ferro, Francesco","Buda, Gabriele","Benedetti, Edoardo","Fazzi, Rita","Baglietto, Laura","Lucenteforte, Ersilia","Di Paolo, Antonello","Petrini, Mario"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387301","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104866","keywords":["baricitinib","begelomab","covid-19","gvhd","mas","ruxolitinib","tkis","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892704931840,"score":53.790203},{"pmid":32480250,"title":"Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.","text":["Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.","Med Hypotheses","Meenakshisundaram, Ramachandran","Senthilkumaran, Subramanian","Thirumalaikolundusubramanian, Ponniah","32480250"],"journal":"Med Hypotheses","authors":["Meenakshisundaram, Ramachandran","Senthilkumaran, Subramanian","Thirumalaikolundusubramanian, Ponniah"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480250","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109849","keywords":["bcg","coronavirus","covid-19","measles","sars","vaccines"],"topics":["Treatment"],"weight":1,"_version_":1668437834947624960,"score":53.25884},{"pmid":32403217,"title":"Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.","text":["Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.","The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations.","J Clin Med","Sardu, Celestino","Gambardella, Jessica","Morelli, Marco Bruno","Wang, Xujun","Marfella, Raffaele","Santulli, Gaetano","32403217"],"abstract":["The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations."],"journal":"J Clin Med","authors":["Sardu, Celestino","Gambardella, Jessica","Morelli, Marco Bruno","Wang, Xujun","Marfella, Raffaele","Santulli, Gaetano"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403217","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/jcm9051417","keywords":["ace2, acute kidney injury","covid","kawasaki disease","blood pressure","catepsin","coronavirus","cytokine storm","endothelium","heparin"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1666802845411704832,"score":47.936005}]}